Blueprint Medicines’ focus on Ayvakit continues to pay off, which has ample untapped revenue potential in advanced and indolent systemic mastocytosis. Additionally, their pipeline includes other ...
Stem cell therapy is an emerging treatment for type 2 diabetes. Although it’s not yet FDA-approved in the United States, it is a rapidly expanding and promising field of research. Stem cells are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results